Currently, there are 63.29M common shares owned by the public and among those 43.42M shares have been available to trade.
The company’s stock has a 5-day price change of 78.36% and 51.27% over the past three months. GALT shares are trading 85.27% year to date (YTD), with the 12-month market performance down to -10.15% lower. It has a 12-month low price of $0.73 and touched a high of $3.17 over the same period. GALT has an average intraday trading volume of 212.87K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 74.90%, 76.61%, and 29.55% respectively.
Institutional ownership of Galectin Therapeutics Inc (NASDAQ: GALT) shares accounts for 15.75% of the company’s 63.29M shares outstanding.
It has a market capitalization of $151.27M and a beta (3y monthly) value of 0.55. The earnings-per-share (ttm) stands at -$0.72. Price movements for the stock have been influenced by the stock’s volatility, which stands at 21.83% over the week and 10.80% over the month.
Earnings per share for the fiscal year are expected to increase by 11.84%, and 2.99% over the next financial year. EPS should grow at an annualized rate of 5.57% over the next five years, compared to -23.89% over the past 5-year period.
Looking at the support for the GALT, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on June 17, 2025, with the firm’s price target at $6. H.C. Wainwright coverage for the Galectin Therapeutics Inc (GALT) stock in a research note released on August 13, 2020 offered a Buy rating with a price target of $12. B. Riley FBR was of a view on February 13, 2019 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on December 07, 2017, issuing a price target of $6- $10. H.C. Wainwright on their part issued Buy rating on November 28, 2017.
